Staying ahead of today’s ever changing diagnostic innovation landscape requires a fast and flexible product development process to ensure that innovative ideas have a clear and accelerated path to market. InSilixa has built the HYDRA-1K CMOS Biochip platform to ensure that our partners can readily convert known disease causing mutations to clinical trial ready solutions in as little as 6 months.
As our partner, once you identify your targets, InSilixa will work with you to design and optimize your assay using a rapid prototyping system, designated the “Developers Platform”. This expedites assay optimization prior to its transfer to the integrated HYDRA-1K cartridge. Within the 6 months target-to-trial window, your CMOS biochip platform will be ready for final qualification and clinical trial initiation!